LU91206I2 - Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel) - Google Patents

Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel)

Info

Publication number: LU91206I2
Authority: LU; Luxembourg
Prior art keywords: ceftiofur; free acid; naxcel; pharmaceutically acceptable; crystalline free
Prior art date: 1993-03-12

Application number

LU91206C

Other languages

English (en)

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-12

Filing date

2005-11-16

Publication date

2006-05-30

2005-11-16 Application filed by Upjohn Co filed Critical Upjohn Co

2006-05-30 Publication of LU91206I2 publication Critical patent/LU91206I2/fr

Links

ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 title abstract 3
239000002253 acid Substances 0.000 title abstract 2
229960005229 ceftiofur Drugs 0.000 title abstract 2
229940017578 naxcel Drugs 0.000 title 1
229930186147 Cephalosporin Natural products 0.000 abstract 1
229940124587 cephalosporin Drugs 0.000 abstract 1
150000001780 cephalosporins Chemical class 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Virology (AREA)
Cephalosporin Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

LU91206C 1993-03-12 2005-11-16 Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel) LU91206I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3329193A	1993-03-12	1993-03-12
PCT/US1994/001862 WO1994020505A1 (fr)	1993-03-12	1994-03-07	Acide libre cristallin de ceftiofur_______________________

Publications (1)

Publication Number	Publication Date
LU91206I2 true LU91206I2 (fr)	2006-05-30

Family

ID=21869579

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91206C LU91206I2 (fr)	1993-03-12	2005-11-16	Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel)

Country Status (31)

Country	Link
US (1)	US5721359A (fr)
EP (1)	EP0690864B1 (fr)
JP (1)	JP3852946B2 (fr)
KR (1)	KR100296810B1 (fr)
CN (1)	CN1055090C (fr)
AT (1)	ATE202109T1 (fr)
AU (1)	AU694419B2 (fr)
BR (1)	BR1101034A (fr)
CA (1)	CA2155322C (fr)
CZ (1)	CZ289332B6 (fr)
DE (2)	DE69427469T2 (fr)
DK (1)	DK0690864T3 (fr)
ES (1)	ES2157254T3 (fr)
FI (1)	FI120307B (fr)
FR (1)	FR05C0045I2 (fr)
GR (1)	GR3036514T3 (fr)
HU (1)	HU222244B1 (fr)
IL (1)	IL108910A (fr)
LU (1)	LU91206I2 (fr)
LV (1)	LV12889B (fr)
NL (1)	NL300208I2 (fr)
NO (2)	NO313199B1 (fr)
NZ (1)	NZ263002A (fr)
PL (1)	PL184611B1 (fr)
PT (1)	PT690864E (fr)
RU (1)	RU2136685C1 (fr)
SI (1)	SI0690864T1 (fr)
SK (1)	SK283674B6 (fr)
TW (1)	TW267170B (fr)
WO (1)	WO1994020505A1 (fr)
ZA (1)	ZA941586B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5736151A (en) *	1996-12-09	1998-04-07	Pharmacia & Upjohn Company	Antibiotic oil suspensions
US6074657A (en) *	1997-03-20	2000-06-13	Pharmacia & Upjohn Company	Administration of an injectable antibiotic in the ear of an animal
US7829100B2 (en) *	2000-09-12	2010-11-09	Teagarden Dirk L	Pharmaceutical composition having modified carrier
MXPA03002055A (es) *	2000-09-12	2004-12-13	Upjohn Co	Composicion farmaceutica con excipiente modificado.
KR100423895B1 (ko) *	2001-02-19	2004-03-24	주식회사 엘지생명과학	셉티오퍼 하이드로클로라이드의 현탁제 조성물
CA2453182A1 (fr) *	2001-07-10	2003-01-23	Meredith L. Greene	Cristaux a base de thiazine oxazolidinones
CN100364991C (zh) *	2001-08-15	2008-01-30	法玛西雅厄普约翰美国公司	2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
JP4365222B2 (ja)	2002-03-21	2009-11-18	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	注射用抗生物質を動物の耳に投与する方法
US20040022815A1 (en) *	2002-08-05	2004-02-05	Orchid Health Care	Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) *	2002-08-13	2004-02-19	대한뉴팜(주)	세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US20040115822A1 (en) *	2002-09-12	2004-06-17	Schapaugh Randal Lee	Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition
US7659061B2 (en) *	2002-11-19	2010-02-09	Pharmacia & Upjohn Company	Pharmaceutical compositions having a modified vehicle
US20040115837A1 (en) *	2002-11-27	2004-06-17	Schapaugh Randal Lee	Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition
US7842791B2 (en) *	2002-12-19	2010-11-30	Nancy Jean Britten	Dispersible pharmaceutical compositions
ES2329244T3 (es) *	2003-03-27	2009-11-24	Basilea Pharmaceutica Ag	Cefalosporina en forma cristalina.
KR101836467B1 (ko) *	2004-03-25	2018-03-08	아스텔라스세이야쿠 가부시키가이샤	솔리페나신 또는 그의 염의 고형 제제용 조성물
US7815939B2 (en)	2005-07-20	2010-10-19	Astellas Pharma Inc.	Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
US8212024B2 (en) *	2005-10-12	2012-07-03	Orchid Chemicals & Pharmaceuticals Ltd.	Crystalline sodium salt of cephalosporin antibiotic
US8470809B2 (en) *	2005-10-12	2013-06-25	Orchid Chemicals & Pharmaceuticals Limited	Crystalline sodium salt of cephalosporin antibiotic
DK2195293T3 (da)	2007-08-22	2014-02-03	Astrazeneca Ab	Cyclopropylamidderivater
US9943614B2 (en)	2008-06-17	2018-04-17	Brigham Young University	Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
US8431562B2 (en) *	2008-08-22	2013-04-30	Orchid Chemicals & Pharmaceuticals Limited	Crystalline sodium salt of cephalosporin antibiotic
JP5685193B2 (ja) *	2008-11-19	2015-03-18	メリアルリミテッド	セフチオフルおよびケトプロフェンとまたはセフチオフルとベンジルアルコールとを含む製剤
CN102405047B (zh) *	2009-01-30	2014-07-09	葛兰素史密斯克莱有限责任公司	结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
TW201039825A (en)	2009-02-20	2010-11-16	Astrazeneca Ab	Cyclopropyl amide derivatives 983
BR112012020629A2 (pt)	2010-02-18	2018-06-19	Astrazeneca Ab	forma cristalina, e, método para a terapia de um distúrbio
US20110201622A1 (en) *	2010-02-18	2011-08-18	Collins Craig D	Solid Forms Comprising A Cyclopropyl Amide Derivative
JP2014513116A (ja) *	2011-05-02	2014-05-29	ゾエティス・エルエルシー	抗菌剤として有用な新規セファロスポリン
CN104053458B (zh)	2011-07-20	2016-07-20	布莱阿姆青年大学	包含洗脱塞拉集宁化合物的水凝胶材料
US9694019B2 (en)	2011-09-13	2017-07-04	Brigham Young University	Compositions and methods for treating bone diseases and broken bones
US9603859B2 (en)	2011-09-13	2017-03-28	Brigham Young University	Methods and products for increasing the rate of healing of tissue wounds
EP2755661A1 (fr)	2011-09-13	2014-07-23	Brigham Young University	Compositions pour traiter les maladies osseuses et les fractures osseuses
MX369385B (es)	2011-09-13	2019-11-07	Univ Brigham Young	Productos para cicatrizar heridas tisulares.
KR20140116111A (ko)	2011-12-21	2014-10-01	브라이엄 영 유니버시티	구강 관리 조성물
CN102584855B (zh) *	2012-02-16	2014-06-25	青岛科技大学	一种改进的头孢噻呋的制备方法
US9533063B1 (en)	2012-03-01	2017-01-03	Brigham Young University	Aerosols incorporating ceragenin compounds and methods of use thereof
US10039285B2 (en)	2012-05-02	2018-08-07	Brigham Young University	Ceragenin particulate materials and methods for making same
EP2908826A1 (fr)	2012-10-17	2015-08-26	Brigham Young University	Traitement et prévention de la mastite
WO2014087972A1 (fr) *	2012-12-03	2014-06-12	株式会社カネカ	Dérivé de la coenzyme q10 sous sa forme réduite et procédé de production associé
JP6294352B2 (ja)	2013-01-07	2018-03-14	ブリガム・ヤング・ユニバーシティＢｒｉｇｈａｍＹｏｕｎｇＵｎｉｖｅｒｓｉｔｙ	細胞増殖を減少させ、ある特定の疾患を治療する方法
US11524015B2 (en)	2013-03-15	2022-12-13	Brigham Young University	Methods for treating inflammation, autoimmune disorders and pain
US10568893B2 (en)	2013-03-15	2020-02-25	Brigham Young University	Methods for treating inflammation, autoimmune disorders and pain
WO2014151411A1 (fr)	2013-03-15	2014-09-25	Brigham Young University	Procédés de traitement d'une inflammation, de troubles auto-immuns et de la douleur
RU2546675C2 (ru) *	2013-04-11	2015-04-10	Федеральное казённое предприятие "Государственный научно-исследовательский институт химических продуктов" (ФКП "ГосНИИХП")	Способ определения степени кристалличности составов на основе дифениламина
US9387215B2 (en)	2013-04-22	2016-07-12	Brigham Young University	Animal feed including cationic cholesterol additive and related methods
CN105517992B (zh) *	2013-09-05	2018-06-22	田边三菱制药株式会社	新型结晶性芳烷基胺化合物及其制造方法
US11690855B2 (en)	2013-10-17	2023-07-04	Brigham Young University	Methods for treating lung infections and inflammation
US20150203527A1 (en)	2014-01-23	2015-07-23	Brigham Young University	Cationic steroidal antimicrobials
CA2844321C (fr)	2014-02-27	2021-03-16	Brigham Young University	Composes antimicrobiens steroides cationiques
US10220045B2 (en)	2014-03-13	2019-03-05	Brigham Young University	Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9867836B2 (en)	2014-03-13	2018-01-16	Brigham Young University	Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US9931350B2 (en)	2014-03-14	2018-04-03	Brigham Young University	Anti-infective and osteogenic compositions and methods of use
US9686966B2 (en)	2014-04-30	2017-06-27	Brigham Young University	Methods and apparatus for cleaning or disinfecting a water delivery system
US10441595B2 (en)	2014-06-26	2019-10-15	Brigham Young University	Methods for treating fungal infections
US10238665B2 (en)	2014-06-26	2019-03-26	Brigham Young University	Methods for treating fungal infections
US10227376B2 (en)	2014-08-22	2019-03-12	Brigham Young University	Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en)	2014-10-07	2018-12-18	Brigham Young University	Cationic steroidal antimicrobial prodrug compositions and uses thereof
UA119794C2 (uk) *	2014-10-21	2019-08-12	Аріад Фармасьютикалз, Інк.	Кристалічна форма 5-хлор-n4-[2-(диметилфосфорил)феніл]-n2-{2-метокси-4-[4-(4-метилпіперазин-1-іл)піперидин-1-іл]}піримідин-2,4-діаміну
US9527883B2 (en)	2015-04-22	2016-12-27	Brigham Young University	Methods for the synthesis of ceragenins
US10370403B2 (en)	2015-04-22	2019-08-06	Brigham Young University	Methods for the synthesis of ceragenins
KR101753842B1 (ko) *	2015-05-12	2017-07-04	한국화학연구원	불화퀴놀론계 항생제를 담지한 서방형 제제 및 이의 제조방법
US9434759B1 (en)	2015-05-18	2016-09-06	Brigham Young University	Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
CN106543203B (zh) *	2015-09-18	2019-07-02	瑞普（天津）生物药业有限公司	一种长效头孢噻呋自由酸晶体的制备方法
EP3778567A1 (fr) *	2016-01-22	2021-02-17	Sandoz Ag	Bis-hydrochlorure cristalin d'eravacycline
US10226550B2 (en)	2016-03-11	2019-03-12	Brigham Young University	Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
KR101898282B1 (ko) *	2016-05-24	2018-09-13	주식회사 고려비엔피	항생제의 서방형 수의학적 조성물 및 이의 제조방법
CN109563087A (zh) *	2016-07-07	2019-04-02	铁木医药有限公司	sGC刺激剂的固体形式
US10959433B2 (en)	2017-03-21	2021-03-30	Brigham Young University	Use of cationic steroidal antimicrobials for sporicidal activity
US11186556B1 (en) *	2018-10-16	2021-11-30	Celgene Corporation	Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
UA119735C2 (uk)	2018-12-20	2019-07-25	Анатолій Семенович Редер	Фармацевтична сполука, спосіб її отримання та застосування як лікарського засобу
WO2020231990A1 (fr)	2019-05-13	2020-11-19	Relay Therapeutics, Inc.	Inhibiteurs de fgfr et leurs procédés d'utilisation
US12186328B2 (en)	2019-05-23	2025-01-07	Brigham Young University	Use of CSA compounds to stimulate stem cells and hair growth
TW202233625A (zh) *	2020-11-18	2022-09-01	美商傳達治療有限公司	Ｆｇｆｒ抑制劑及其製造及使用方法
CN117229296A (zh) *	2023-09-14	2023-12-15	广东温氏大华农生物科技有限公司	一种头孢噻呋酸晶体及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1207933B (de) *	1962-12-26	1965-12-30	American Home Prod	Verfahren zur Herstellung von kristallwasser-freiem D-alpha-Aminobenzylpenicillin
US3489751A (en) *	1967-09-05	1970-01-13	Bristol Myers Co	7-amino-cephalosporanic and decephalosporanic acid derivatives
DK154939C (da) *	1974-12-19	1989-06-12	Takeda Chemical Industries Ltd	Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf
DE2760123C2 (de) *	1976-01-23	1986-04-30	Roussel-Uclaf, Paris	7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
GB1532682A (en) *	1976-04-27	1978-11-22	Bristol Myers Co	Process for the preparation of cephadroxil
FR2479229B1 (fr) *	1980-03-26	1986-01-17	Clin Midy	Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
IL63968A (en) *	1980-10-01	1985-10-31	Glaxo Group Ltd	Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4400503A (en) *	1981-10-30	1983-08-23	Eli Lilly And Company	Purification of syn-7-[[(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-3-methyl-3-cephem-4-carboxylic acid
DE3313818A1 (de) *	1983-04-16	1984-10-18	Hoechst Ag, 6230 Frankfurt	Neue kristallmodifikation von ceftazidim
HU196714B (en) *	1984-10-04	1989-01-30	Monsanto Co	Process for producing non-aqueous composition comprising somatotropin
IT1181672B (it) *	1984-10-25	1987-09-30	Upjohn Co	Cefalosporina alogenidrato cristallino
US4902683A (en) *	1984-10-25	1990-02-20	The Upjohn Company	Crystalline cephalosporin hydrohalide salts
FR2585705B1 (fr) *	1985-08-05	1989-01-13	Bristol Myers Co	Sels de cephalosporine et compositions injectables
WO1987001117A2 (fr) *	1985-08-12	1987-02-26	The Upjohn Company	Conversion du sel d'hydrohalogenure de cephalosporine en sel de metal alcalin
GB8608962D0 (en) *	1986-04-12	1986-05-14	Beecham Group Plc	Beta-lactam antibiotics
IT1214587B (it) *	1986-12-23	1990-01-18	Giovanni Bonfanti	Metodo per la produzione diprodotti cristallini puri.
DE3871542T2 (de) *	1987-02-02	1992-12-24	Lilly Co Eli	Verfahren zur herstellung von ceftazidime-pentahydrat.
AU611461B2 (en) *	1987-07-29	1991-06-13	Pharmacia & Upjohn Company	Controlled release of antibiotic salts from an implant
WO1989004313A1 (fr) *	1987-11-10	1989-05-18	The Upjohn Company	Antibiotiques a base de cephalosporine
US4877782A (en) *	1988-02-16	1989-10-31	The Upjohn Company	Zinc ceftiofur complexes

1994
- 1994-03-07 KR KR1019950703858A patent/KR100296810B1/ko not_active Expired - Lifetime
- 1994-03-07 EP EP94910721A patent/EP0690864B1/fr not_active Expired - Lifetime
- 1994-03-07 DK DK94910721T patent/DK0690864T3/da active
- 1994-03-07 WO PCT/US1994/001862 patent/WO1994020505A1/fr not_active Ceased
- 1994-03-07 JP JP52002594A patent/JP3852946B2/ja not_active Expired - Lifetime
- 1994-03-07 ES ES94910721T patent/ES2157254T3/es not_active Expired - Lifetime
- 1994-03-07 RU RU95121942A patent/RU2136685C1/ru active
- 1994-03-07 AT AT94910721T patent/ATE202109T1/de active
- 1994-03-07 AU AU63510/94A patent/AU694419B2/en not_active Expired
- 1994-03-07 PL PL94310556A patent/PL184611B1/pl unknown
- 1994-03-07 SI SI9430374T patent/SI0690864T1/xx unknown
- 1994-03-07 PT PT94910721T patent/PT690864E/pt unknown
- 1994-03-07 NZ NZ263002A patent/NZ263002A/en not_active IP Right Cessation
- 1994-03-07 US US08/549,821 patent/US5721359A/en not_active Expired - Lifetime
- 1994-03-07 SK SK1114-95A patent/SK283674B6/sk not_active IP Right Cessation
- 1994-03-07 DE DE69427469T patent/DE69427469T2/de not_active Expired - Lifetime
- 1994-03-07 DE DE122005000055C patent/DE122005000055I2/de active Active
- 1994-03-07 HU HU9501960A patent/HU222244B1/hu active Protection Beyond IP Right Term
- 1994-03-07 CZ CZ19952290A patent/CZ289332B6/cs unknown
- 1994-03-07 CA CA002155322A patent/CA2155322C/fr not_active Expired - Lifetime
- 1994-03-07 ZA ZA941586A patent/ZA941586B/xx unknown
- 1994-03-07 CN CN94191448A patent/CN1055090C/zh not_active Expired - Lifetime
- 1994-03-09 IL IL10891094A patent/IL108910A/en not_active IP Right Cessation
- 1994-03-12 TW TW083102155A patent/TW267170B/zh not_active IP Right Cessation
1995
- 1995-09-11 FI FI954250A patent/FI120307B/fi not_active IP Right Cessation
- 1995-09-11 NO NO19953564A patent/NO313199B1/no not_active IP Right Cessation
1997
- 1997-05-14 BR BR1101034-7A patent/BR1101034A/pt active IP Right Grant
2001
- 2001-09-04 GR GR20010401374T patent/GR3036514T3/el unknown
2002
- 2002-06-13 LV LVP-02-107A patent/LV12889B/lv unknown
2005
- 2005-11-16 LU LU91206C patent/LU91206I2/fr unknown
- 2005-11-17 FR FR05C0045C patent/FR05C0045I2/fr active Active
- 2005-11-18 NO NO2005025C patent/NO2005025I2/no unknown
- 2005-11-21 NL NL300208C patent/NL300208I2/nl unknown

Also Published As

Publication number	Publication date
FI954250A0 (fi)	1995-09-11
NL300208I1 (nl)	2006-02-01
NO313199B1 (no)	2002-08-26
ZA941586B (en)	1995-09-07
JP3852946B2 (ja)	2006-12-06
DE122005000055I1 (de)	2006-02-23
DE69427469D1 (en)	2001-07-19
FI954250L (fi)	1995-09-11
ATE202109T1 (de)	2001-06-15
EP0690864B1 (fr)	2001-06-13
PT690864E (pt)	2001-11-30
HU9501960D0 (en)	1995-09-28
CN1055090C (zh)	2000-08-02
GR3036514T3 (en)	2001-12-31
DE122005000055I2 (de)	2008-06-05
DE69427469T2 (de)	2001-10-31
WO1994020505A1 (fr)	1994-09-15
NO953564D0 (no)	1995-09-11
CA2155322A1 (fr)	1994-09-15
HUT73781A (en)	1996-09-30
CN1119016A (zh)	1996-03-20
CA2155322C (fr)	2000-02-29
SK283674B6 (sk)	2003-11-04
HU222244B1 (hu)	2003-05-28
RU2136685C1 (ru)	1999-09-10
SK111495A3 (en)	1995-12-06
FR05C0045I1 (fr)	2006-01-06
TW267170B (fr)	1996-01-01
NO953564L (no)	1995-11-07
IL108910A (en)	1999-10-28
KR100296810B1 (ko)	2001-10-24
US5721359A (en)	1998-02-24
EP0690864A1 (fr)	1996-01-10
NO2005025I2 (no)	2010-11-22
FI120307B (fi)	2009-09-15
FR05C0045I2 (fr)	2007-08-03
PL184611B1 (pl)	2002-11-29
CZ9502290A3 (cs)	2001-08-15
NO2005025I1 (no)	2005-12-05
AU6351094A (en)	1994-09-26
PL310556A1 (en)	1995-12-27
JPH08507519A (ja)	1996-08-13
ES2157254T3 (es)	2001-08-16
NL300208I2 (nl)	2006-05-01
BR1101034A (pt)	2002-04-30
LV12889B (lv)	2002-12-20
AU694419B2 (en)	1998-07-23
CZ289332B6 (cs)	2002-01-16
NZ263002A (en)	1996-12-20
DK0690864T3 (da)	2001-09-17
IL108910A0 (en)	1994-06-24
SI0690864T1 (en)	2001-10-31

Publication	Publication Date	Title
LU91206I2 (fr)	2006-05-30	Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel)
IL108520A0 (en)	1994-05-30	Imidazopyridine derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them
TW252979B (fr)	1995-08-01
HU9402466D0 (en)	1994-10-28	Indole derivatives as steroid-5-alpha-reductase inhibitors
AU6303996A (en)	1997-01-22	Mono- and disulfo-substituted anthraquinones and their use for the treatment of bone matrix disorders
HRP950437A2 (en)	1997-08-31	N-substituted azabicycloheptane derivatives, their production and use
DE69318715D1 (de)	1998-06-25	Pharmakologisch aktive alpha-(tertiär-aminoethyl)-phenylmethanol-derivate
IL107232A0 (en)	1994-01-25	19, 11-bridged 4-estrene derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
ES2087567T3 (es)	1996-07-16	Derivados antibioticos de 7'-amino-naftazarina.
DK0646113T3 (fr)	1997-02-24
NO961061L (no)	1996-03-15	Terapeutisk aktive antracyclin-disakkarider
AU7000994A (en)	1995-01-17	Phosphosuccinic acid derivatives and their use as medicaments
IL99369A0 (en)	1992-08-18	Pharmaceutical compositions containing substituted 2-cyclohexene derivatives